AntibodySystem ADC & AAV Research Products
Antibodies, recombinant proteins, and assay-related reagents for oncology drug discovery and gene therapy vector research
What is an Antibody-Drug Conjugate, ADC?
Antibody-drug conjugates, ADCs, are an innovative class of targeted anticancer therapeutics designed to selectively deliver highly potent cytotoxic agents to cancer cells. A typical ADC consists of three precisely engineered components: a monoclonal antibody, a chemical linker, and a cytotoxic payload.
The antibody component specifically recognizes a tumor-associated antigen expressed on the cancer cell surface. After binding, the antibody-antigen complex is internalized into the cell. Once inside the lysosomal compartment, the linker is cleaved or destabilized, enabling the release of the cytotoxic payload. The released payload can induce tumor cell apoptosis through mechanisms such as DNA damage or disruption of microtubule dynamics.
ADCs are designed to combine the selectivity of antibody-based targeting with the potency of small-molecule cytotoxic drugs. This targeted delivery strategy can enhance antitumor efficacy while improving the therapeutic safety window compared with conventional systemic chemotherapy. However, ADC development remains technically demanding and requires optimization of multiple parameters, including target selection, antibody properties, linker stability, drug-to-antibody ratio, conjugation strategy, in vivo delivery, and controlled payload release.
Target Antigen
The target antigen is typically a tumor-associated surface marker that enables selective recognition of cancer cells. Target expression, internalization behavior, tissue distribution, and tumor specificity are critical factors in ADC design and evaluation.
Monoclonal Antibody
The antibody acts as the guidance system that directs the cytotoxic payload to antigen-positive cancer cells. Binding affinity, specificity, stability, internalization capacity, and antibody format all influence ADC performance.
Linker
The linker connects the antibody to the cytotoxic payload. An ideal linker remains stable in circulation but allows efficient payload release inside target cells. Linker stability and cleavage mechanism directly affect efficacy and safety.
Cytotoxic Payload
The payload is the warhead responsible for destroying cancer cells. Common ADC payload research areas include DXd/Deruxtecan, DM1, SN38, MMAE, and MMAF. Payload-specific antibodies are useful tools for ADC detection and characterization.
AntibodySystem ADC-Related Product Portfolio
AntibodySystem provides a growing portfolio of research-use ADC-related reagents, including payload-specific antibodies, ADC reference materials, and recombinant target proteins. These products can support ADC candidate screening, payload detection, target validation, binding assay development, and ADC mechanism studies.
| ADC Product Group | Key Examples | Research Applications |
|---|---|---|
| Payload-Specific Antibodies | Anti-Deruxtecan/DXd, Anti-DM1, Anti-SN38, Anti-MMAE, Anti-MMAF | Payload detection, ADC analysis, conjugation confirmation |
| ADC Reference Materials | Cetuximab-MMAE, Trastuzumab-MMAE, Trastuzumab emtansine, Sacituzumab govitecan | Assay controls, comparative studies, ADC workflow validation |
| Recombinant Target Proteins | CDH17, DLL3, ADAM9, CA9 and other ADC target-related proteins | Binding assays, target validation, antibody screening |
What is Adeno-Associated Virus, AAV?
Adeno-associated virus, AAV, is a non-enveloped, single-stranded DNA virus from the Parvoviridae family. With an approximate size of 25 nm, AAV has an icosahedral capsid composed of VP1, VP2, and VP3 proteins. AAV vectors are widely used in gene therapy research because of their favorable safety profile, low immunogenicity, and ability to support stable gene expression.
Multiple AAV serotypes, including AAV1 through AAV9, enable targeted delivery to different tissues such as liver, muscle, retina, brain, heart, lung, and the central nervous system. Serotype selection is therefore a key consideration in AAV vector design, tissue tropism studies, and gene delivery optimization.
AAV research often requires reliable tools for capsid protein detection, serotype characterization, vector titer analysis, neutralization assays, process development, and quality control research. High-specificity antibodies and ELISA-based reagents are essential for accurate AAV vector analysis and reproducible assay development.
Comprehensive Coverage
AntibodySystem offers antibodies targeting major AAV serotypes and capsid proteins, including VP1/capsid-related targets for AAV2, AAV8, AAV9, and broader serotype coverage.
High Specificity & Sensitivity
In AAV vector analysis, specificity and sensitivity are essential for serotype discrimination, capsid detection, and assay reliability. Proper antibody selection can help improve reproducibility in AAV characterization workflows.
Multiple Applications
AntibodySystem AAV-related antibodies are available for various applications, including ELISA, Western Blot, immunofluorescence, immunohistochemistry, immunoprecipitation, dot blot, and neutralization research.
Validated Research Quality
AAV research reagents support vector characterization, capsid detection, process development, QC research, and assay validation where consistency and reproducibility are essential.
AntibodySystem AAV-Related Product Portfolio
AntibodySystem provides antibodies, ELISA-related products, and proteins for AAV research, characterization, and process development. These reagents are suitable for AAV capsid detection, serotype-specific analysis, vector quality evaluation, neutralization research, and assay development.
| AAV Product Group | Targets / Serotypes | Applications |
|---|---|---|
| AAV2 Capsid Antibodies | AAV2 VP1 / Capsid protein VP1 | ELISA, IF, WB, capsid detection |
| AAV9 Capsid Antibodies | AAV9 VP1 / Capsid protein VP1 | ELISA, WB, IFA, IHC, CLIA, IP |
| Intact Particle Antibodies | AAV2, AAV8, AAV6 intact particle and related capsid targets | Dot blot, ELISA, neutralization, capsid integrity analysis |
| Broad Serotype Antibodies | AAV1/2/5/6/8/9 and other serotype combinations | Serotype screening, vector comparison, process development |
Recommended Research Applications
ADC Research
- ADC candidate screening
- Payload-specific antibody detection
- Drug-to-antibody ratio-related analytical studies
- Target antigen binding assays
- Internalization and payload release studies
- Oncology drug discovery workflow development
AAV Research
- AAV capsid detection
- AAV serotype characterization
- Gene therapy vector research
- ELISA-based assay development
- Process development and QC research
- Neutralization assays and vector analysis
Source AntibodySystem Products through Dana Bioscience
Dana Bioscience supports researchers and biotech teams seeking AntibodySystem ADC and AAV research products. When selecting the right product, catalog number, target, application, host, species, size, assay format, and research objective can all be important considerations.
For ADC research, product selection may depend on payload type, target antigen, antibody format, binding assay design, and detection strategy. For AAV research, product selection may depend on serotype, capsid target, application, intact particle recognition, and vector characterization requirements.
Dana Bioscience can assist with product recommendation, alternative product matching, quotation support, lead time check, and product comparison for your research workflow.
Contact Dana Bioscience for AntibodySystem ADC & AAV Products
If you are looking for antibodies, recombinant proteins, or assay-related reagents for ADC development research or AAV gene therapy vector studies, Dana Bioscience can help you identify suitable AntibodySystem products.
Product recommendation · Quotation support · Lead time check · Alternative product matching · Research workflow review
All products are for research use only. Not for diagnostic or therapeutic use.